{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:54:42Z","timestamp":1788382482133,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/1\/2(12)\/OBS\/2022-NCD-II"],"award-info":[{"award-number":["3\/1\/2(12)\/OBS\/2022-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10249-0","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:57Z","timestamp":1738061997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-7485","authenticated-orcid":false,"given":"Monika","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-6248","authenticated-orcid":false,"given":"Papiya Mitra","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"10249_CR1","doi-asserted-by":"publisher","unstructured":"Cho NH, Shaw JE, Karuranga S et al (2018) Diabetes Res Clin Pract 138:271\u2013281. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","DOI":"10.1016\/j.diabres.2018.02.023"},{"issue":"2","key":"10249_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/biomedicines11020468","volume":"11","author":"E Vetrano","year":"2023","unstructured":"Vetrano E, Rinaldi L, Mormone A et al (2023) Non-alcoholic fatty liver Disease (NAFLD), type 2 diabetes, and non-viral Hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies. Biomedicines 11(2):468. https:\/\/doi.org\/10.3390\/biomedicines11020468","journal-title":"Biomedicines"},{"issue":"2","key":"10249_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR (2021) Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a Decade. Hepatology 73(2):833\u2013842. https:\/\/doi.org\/10.1002\/hep.31518","journal-title":"Hepatology"},{"key":"10249_CR4","doi-asserted-by":"publisher","unstructured":"Mantovani A, Turino T, Lando MG et al (2020) Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab 46(4):296\u2013303. https:\/\/doi.org\/10.1016\/j.diabet.2019.11.004","DOI":"10.1016\/j.diabet.2019.11.004"},{"issue":"21","key":"10249_CR5","doi-asserted-by":"publisher","first-page":"11629","DOI":"10.3390\/ijms222111629","volume":"22","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J (2021) Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with Cardiovascular diseases. Int J Mol Sci 22(21):11629. https:\/\/doi.org\/10.3390\/ijms222111629","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10249_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole JB, Florez JC (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 16(7):377\u2013390. https:\/\/doi.org\/10.1038\/s41581-020-0278-5","journal-title":"Nat Rev Nephrol"},{"key":"10249_CR7","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/DDDT.S207277","volume":"13","author":"DY Zhang","year":"2019","unstructured":"Zhang DY, Zhu L, Liu HN et al (2019) The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 13:2249\u20132270. https:\/\/doi.org\/10.2147\/DDDT.S207277","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10249_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-019-1107-y","volume":"21","author":"D Glovaci","year":"2019","unstructured":"Glovaci D, Fan W, Wong ND (2019) Epidemiology of diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep 21(4):21. https:\/\/doi.org\/10.1007\/s11886-019-1107-y","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10249_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H (2020) Nonalcoholic fatty liver Disease Pandemic fuels the Upsurge in Cardiovascular diseases. Circ Res 126(5):679\u2013704. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316337","journal-title":"Circ Res"},{"key":"10249_CR10","doi-asserted-by":"publisher","unstructured":"Liu J, Ayada I, Zhang X et al (2022) Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 20(3):e573-e582. https:\/\/doi.org\/10.1016\/j.cgh.2021.02.030","DOI":"10.1016\/j.cgh.2021.02.030"},{"issue":"8","key":"10249_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/life12081189","volume":"12","author":"GD Cazac","year":"2024","unstructured":"Cazac GD, L\u0103c\u0103tu\u0219u CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM (2024) New insights into non-alcoholic fatty liver Disease and Coronary Artery Disease: the Liver-Heart Axis. Life (Basel) 12(8):1189. https:\/\/doi.org\/10.3390\/life12081189","journal-title":"Life (Basel)"},{"issue":"7","key":"10249_CR12","doi-asserted-by":"publisher","first-page":"e13519","DOI":"10.1111\/eci.13519","volume":"51","author":"P Dongiovanni","year":"2021","unstructured":"Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M (2021) Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: from epidemiology to drug approaches. Eur J Clin Invest 51(7):e13519. https:\/\/doi.org\/10.1111\/eci.13519","journal-title":"Eur J Clin Invest"},{"key":"10249_CR13","doi-asserted-by":"publisher","first-page":"i4428","DOI":"10.1136\/bmj.i4428","volume":"354","author":"J Glen","year":"2016","unstructured":"Glen J, Floros L, Day C, Pryke R (2016) Guideline Development Group. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 354:i4428. https:\/\/doi.org\/10.1136\/bmj.i4428","journal-title":"BMJ"},{"issue":"1","key":"10249_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/07853890.2021.1943514","volume":"53","author":"CO Lee","year":"2021","unstructured":"Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY (2021) Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999\u20132016. Ann Med 53(1):1065\u20131073. https:\/\/doi.org\/10.1080\/07853890.2021.1943514","journal-title":"Ann Med"},{"key":"10249_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbacli.2016.03.002","volume":"5","author":"TW Jung","year":"2016","unstructured":"Jung TW, Yoo HJ, Choi KM (2016) Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin 5:108\u2013113 Published 2016 Mar 5. https:\/\/doi.org\/10.1016\/j.bbacli.2016.03.002","journal-title":"BBA Clin"},{"issue":"1","key":"10249_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","volume":"16","author":"MCS Wong","year":"2019","unstructured":"Wong MCS, Huang JLW, George J et al (2019) The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 16(1):57\u201373. https:\/\/doi.org\/10.1038\/s41575-018-0055-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10249_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5009\/gnl20127","volume":"15","author":"S Murag","year":"2021","unstructured":"Murag S, Ahmed A, Kim D (2021) Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver 15(2):206\u2013216. https:\/\/doi.org\/10.5009\/gnl20127","journal-title":"Gut Liver"},{"issue":"1","key":"10249_CR18","doi-asserted-by":"publisher","first-page":"bnz009","DOI":"10.1210\/endrev\/bnz009","volume":"41","author":"T Marjot","year":"2020","unstructured":"Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW (2020) Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev 41(1):bnz009. https:\/\/doi.org\/10.1210\/endrev\/bnz009","journal-title":"Endocr Rev"},{"key":"10249_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","volume":"5","author":"S Mitra","year":"2020","unstructured":"Mitra S, De A, Chowdhury A (2020) Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol 5:16. https:\/\/doi.org\/10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"4","key":"10249_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"issue":"5","key":"10249_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH et al (2019) Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 4(5):389\u2013398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10249_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/dom.12973","volume":"19","author":"K Cusi","year":"2017","unstructured":"Cusi K, Sanyal AJ, Zhang S et al (2017) Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19(11):1630\u20131634. https:\/\/doi.org\/10.1111\/dom.12973","journal-title":"Diabetes Obes Metab"},{"key":"10249_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","volume":"100","author":"M de Vries","year":"2022","unstructured":"de Vries M, El-Morabit F, van Erpecum KJ et al (2022) Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. Eur J Intern Med 100:77\u201382. https:\/\/doi.org\/10.1016\/j.ejim.2022.03.025","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10249_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.15163","volume":"49","author":"S Sookoian","year":"2019","unstructured":"Sookoian S, Pirola CJ (2019) Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside. Aliment Pharmacol Ther 49(5):516\u2013527. https:\/\/doi.org\/10.1111\/apt.15163","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10249_CR25","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X et al (2022) Estimating Global Prevalence of Metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol 20(3):e573\u2013e582. https:\/\/doi.org\/10.1016\/j.cgh.2021.02.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10249_CR26","doi-asserted-by":"publisher","unstructured":"Tanase DM, Gosav EM, Costea CF et al (2020) The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res 2020:3920196. https:\/\/doi.org\/10.1155\/2020\/3920196","DOI":"10.1155\/2020\/3920196"},{"issue":"9","key":"10249_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H (2020) NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69(9):1691\u20131705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"10249_CR28","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","volume":"6","author":"S Wu","year":"2026","unstructured":"Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z (2026) Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 6:33386. https:\/\/doi.org\/10.1038\/srep33386","journal-title":"Sci Rep"},{"issue":"5","key":"10249_CR29","doi-asserted-by":"publisher","first-page":"e25495","DOI":"10.7759\/cureus.25495","volume":"14","author":"G Hassen","year":"2022","unstructured":"Hassen G, Singh A, Belete G et al (2022) Nonalcoholic fatty liver disease: an emerging modern-day risk factor for Cardiovascular Disease. Cureus 14(5):e25495. https:\/\/doi.org\/10.7759\/cureus.25495","journal-title":"Cureus"},{"key":"10249_CR30","doi-asserted-by":"publisher","first-page":"155220","DOI":"10.1016\/j.metabol.2022.155220","volume":"133","author":"H Peng","year":"2022","unstructured":"Peng H, Wang S, Wang M et al (2022) Nonalcoholic fatty liver disease and cardiovascular diseases: a mendelian randomization study. Metabolism 133:155220. https:\/\/doi.org\/10.1016\/j.metabol.2022.155220","journal-title":"Metabolism"},{"issue":"8","key":"10249_CR31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/hep4.1387","volume":"3","author":"P Golabi","year":"2019","unstructured":"Golabi P, Fukui N, Paik J, Sayiner M, Mishra A, Younossi ZM (2019) Mortality risk detected by atherosclerotic Cardiovascular Disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun 3(8):1050\u20131060. https:\/\/doi.org\/10.1002\/hep4.1387","journal-title":"Hepatol Commun"},{"issue":"8","key":"10249_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson D, Finck BN (2021) Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 17(8):484\u2013495. https:\/\/doi.org\/10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10249_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"10249_CR34","doi-asserted-by":"publisher","first-page":"100161","DOI":"10.1016\/j.deman.2023.100161","volume":"12","author":"A Sinha","year":"2023","unstructured":"Sinha A, Bankura B (2023) Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the eastern region of India. Diabet Epidemiol Manag 12:100161. https:\/\/doi.org\/10.1016\/j.deman.2023.100161","journal-title":"Diabet Epidemiol Manag"},{"issue":"3","key":"10249_CR35","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jceh.2021.11010","volume":"12","author":"EA Shalimar","year":"2022","unstructured":"Shalimar EA, Bansal B, Gupta H, Anand A, Singh TP, Goel A (2022) Prevalence of non-alcoholic fatty liver disease in India: a systematic review and Meta-analysis. J Clin Exp Hepatol 12(3):818\u2013829. https:\/\/doi.org\/10.1016\/j.jceh.2021.11010","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"10249_CR36","first-page":"448","volume":"61","author":"S Kalra","year":"2013","unstructured":"Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, Das B, Sahay R, Modi KD (2013) Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Phys India 61(7):448\u2013453","journal-title":"J Assoc Phys India"},{"issue":"2","key":"10249_CR37","doi-asserted-by":"publisher","first-page":"e3386","DOI":"10.1002\/dmrr.3386","volume":"37","author":"S Cernea","year":"2021","unstructured":"Cernea S, Raz I (2021) NAFLD in type 2 diabetes mellitus: still many challenging questions. Diabetes Metab Res Rev 37(2):e3386. https:\/\/doi.org\/10.1002\/dmrr.3386","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10249_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR (2021) Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a Decade. Hepatol 73(2):833\u2013842. https:\/\/doi.org\/10.1002\/hep.31518","journal-title":"Hepatol"},{"key":"10249_CR39","doi-asserted-by":"publisher","unstructured":"Maru\u0161i\u0107 M, Pai\u0107 M, Knobloch M, Liberati Pr\u0161o AM (2021) NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 6613827. Published 2021 Feb 17. https:\/\/doi.org\/10.1155\/2021\/6613827","DOI":"10.1155\/2021\/6613827"},{"issue":"2","key":"10249_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antiox10020270","volume":"10","author":"L Rinaldi","year":"2021","unstructured":"Rinaldi L, Pafundi PC, Galiero R et al (2021) Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxid (Basel) 10(2):270 Published 2021 Feb 10. https:\/\/doi.org\/10.3390\/antiox10020270","journal-title":"Antioxid (Basel)"},{"key":"10249_CR41","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","volume":"111S","author":"B Dewidar","year":"2020","unstructured":"Dewidar B, Kahl S, Pafili K, Roden M (2020) Metabolic liver disease in diabetes - from mechanisms to clinical trials. Metab 111S:154299. https:\/\/doi.org\/10.1016\/j.metabol.2020.154299","journal-title":"Metab"},{"issue":"2","key":"10249_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","volume":"8","author":"WP Esler","year":"2019","unstructured":"Esler WP, Bence KK (2019) Metabolic targets in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol 8(2):247\u2013267. https:\/\/doi.org\/10.1016\/j.jcmgh.2019.04.007","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"10249_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","volume":"36","author":"A Bayoumi","year":"2020","unstructured":"Bayoumi A, Gr\u00f8nb\u00e6k H, George J, Eslam M (2020) The epigenetic drug Discovery Landscape for metabolic-associated fatty liver disease. Trends Genet 36(6):429\u2013441. https:\/\/doi.org\/10.1016\/j.tig.2020.03.003","journal-title":"Trends Genet"},{"key":"10249_CR44","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fphar.2019.00877","volume":"10","author":"MF Xia","year":"2019","unstructured":"Xia MF, Bian H, Gao X (2019) NAFLD and Diabetes: two sides of the same Coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol 10:877. https:\/\/doi.org\/10.3389\/fphar.2019.00877","journal-title":"Front Pharmacol"},{"issue":"3","key":"10249_CR45","doi-asserted-by":"publisher","first-page":"C420","DOI":"10.1152\/ajpcell.00141.2019","volume":"317","author":"P Newsholme","year":"2019","unstructured":"Newsholme P, Keane KN, Carlessi R, Cruzat V (2019) Oxidative stress pathways in pancreatic \u03b2-cells and insulin-sensitive cells and tissues: importance to cell metabolism, function, and dysfunction. Am J Physiol Cell Physiol 317(3):C420\u2013C433. https:\/\/doi.org\/10.1152\/ajpcell.00141.2019","journal-title":"Am J Physiol Cell Physiol"},{"issue":"12","key":"10249_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1507\/endocrj.EJ19-0263","volume":"66","author":"C Guo","year":"2019","unstructured":"Guo C, Zhao Z, Deng X, Chen Z, Tu Z, Yuan G (2019) Regulation of angiopoietin-like protein 8 expression under different nutritional and metabolic status. Endocr J 66(12):1039\u20131046. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0263","journal-title":"Endocr J"},{"issue":"6","key":"10249_CR47","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1152\/physiol.00013.2023","volume":"38","author":"M Li","year":"2023","unstructured":"Li M, Wang H, Zhang XJ, Cai J, Li H (2023) NAFLD: an emerging causal factor for Cardiovascular Disease. Physiol (Bethesda) 38(6):0. https:\/\/doi.org\/10.1152\/physiol.00013.2023","journal-title":"Physiol (Bethesda)"},{"key":"10249_CR48","doi-asserted-by":"publisher","first-page":"1125829","DOI":"10.3389\/fendo.2023.1125829","volume":"14","author":"Y Cao","year":"2023","unstructured":"Cao Y, Du Y, Jia W et al (2023) Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning. Front Endocrinol (Lausanne) 14:1125829. https:\/\/doi.org\/10.3389\/fendo.2023.1125829","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10249_CR49","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4093\/dmj.2017.41.6.430","volume":"41","author":"E Han","year":"2017","unstructured":"Han E, Lee YH (2017) Non-alcoholic fatty liver disease: the emerging Burden in Cardiometabolic and Renal diseases. Diabetes Metab J 41(6):430\u2013437. https:\/\/doi.org\/10.4093\/dmj.2017.41.6.430","journal-title":"Diabetes Metab J"},{"issue":"9","key":"10249_CR50","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.numecd.2021.05.027","volume":"31","author":"F Vadini","year":"2021","unstructured":"Vadini F, Simeone PG, Desideri G et al (2021) Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. Nutr Metab Cardiovasc Dis 31(9):2685\u20132692. https:\/\/doi.org\/10.1016\/j.numecd.2021.05.027","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"10249_CR51","doi-asserted-by":"publisher","first-page":"755","DOI":"10.31083\/j.rcm2203082","volume":"22","author":"R Galiero","year":"2021","unstructured":"Galiero R, Caturano A, Vetrano E et al (2021) Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med 22(3):755\u2013768. https:\/\/doi.org\/10.31083\/j.rcm2203082","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10249_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/MOL.0000000000000652","volume":"31","author":"G Bedogni","year":"2020","unstructured":"Bedogni G, Gastaldelli A, Foschi FG (2020) Fatty liver, cardiometabolic disease and mortality. Curr Opin Lipidol 31(1):27\u201331. https:\/\/doi.org\/10.1097\/MOL.0000000000000652","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10249_CR53","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.26672","volume":"59","author":"AL Birkenfeld","year":"2014","unstructured":"Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59(2):713\u2013723. https:\/\/doi.org\/10.1002\/hep.26672","journal-title":"Hepatology"},{"issue":"4","key":"10249_CR54","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.aohep.2022.100751","volume":"28","author":"D Garc\u00eda-Compe\u00e1n","year":"2023","unstructured":"Garc\u00eda-Compe\u00e1n D, Kumar R, Cueto-Aguilera \u00c1ND, Maldonado-Garza HJ, Villarreal-P\u00e9rez JZ (2023) Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. Ann Hepatol 28(4):100751. https:\/\/doi.org\/10.1016\/j.aohep.2022.100751","journal-title":"Ann Hepatol"},{"issue":"2","key":"10249_CR55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","volume":"80","author":"WP Esler","year":"2023","unstructured":"Esler WP, Cohen DE (2023) Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. J Hepatol 80(2):362\u2013377. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.042","journal-title":"J Hepatol"},{"issue":"3","key":"10249_CR56","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146(3):726\u2013735. https:\/\/doi.org\/10.1053\/j.gastro.2013.11.049","journal-title":"Gastroenterology"},{"issue":"6","key":"10249_CR57","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"L Parlati","year":"2021","unstructured":"Parlati L, R\u00e9gnier M, Guillou H, Postic C (2021) New targets for NAFLD. JHEP Rep 3(6):100346. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100346","journal-title":"JHEP Rep"},{"issue":"1","key":"10249_CR58","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12967-023-04367-1","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang S, Wu J, Wang Y (2023) Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med 21(1):510 Published 2023 Jul 28. https:\/\/doi.org\/10.1186\/s12967-023-04367-1","journal-title":"J Transl Med"},{"issue":"29","key":"10249_CR59","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2174\/1389203720666190830163735","volume":"25","author":"CD Veloso","year":"2019","unstructured":"Veloso CD, Belew GD, Ferreira LL et al (2019) A mitochondrial Approach to Cardiovascular Risk and Disease. Curr Pharm Des 25(29):3175\u20133194. https:\/\/doi.org\/10.2174\/1389203720666190830163735","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10249_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/07853890.2017.1417631","volume":"50","author":"DA Chistiakov","year":"2018","unstructured":"Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN (2018) The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann Med 50(2):121\u2013127. https:\/\/doi.org\/10.1080\/07853890.2017.1417631","journal-title":"Ann Med"},{"issue":"13","key":"10249_CR61","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.3390\/ijms23137280","volume":"23","author":"R Ramanathan","year":"2022","unstructured":"Ramanathan R, Ali AH, Ibdah JA (2022) Mitochondrial dysfunction plays central role in nonalcoholic fatty liver disease. Int J Mol Sci 23(13):7280. https:\/\/doi.org\/10.3390\/ijms23137280","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10249_CR62","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00210-022-02234-2","volume":"395","author":"U Sabir","year":"2022","unstructured":"Sabir U, Irfan HM, Alamgeer, Umer I, Niazi ZR, Asjad HMM (2022) Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 395(7):741\u2013755. https:\/\/doi.org\/10.1007\/s00210-022-02234-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10249_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/HEP.0000000000000307","volume":"78","author":"D Kundu","year":"2023","unstructured":"Kundu D, Kennedy L, Zhou T et al (2023) p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1\/FOXO1\/IGF-1 signaling. Hepatology 78(1):243\u2013257. https:\/\/doi.org\/10.1097\/HEP.0000000000000307","journal-title":"Hepatology"},{"issue":"8","key":"10249_CR64","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/ijms17081225","volume":"17","author":"M Sanduzzi Zamparelli","year":"2016","unstructured":"Sanduzzi Zamparelli M, Compare D, Coccoli P et al (2016) The metabolic role of gut microbiota in the development of nonalcoholic fatty liver Disease and Cardiovascular Disease. Int J Mol Sci 17(8):1225. https:\/\/doi.org\/10.3390\/ijms17081225","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10249_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/nu14010103","volume":"14","author":"K Dro\u017cd\u017c","year":"2021","unstructured":"Dro\u017cd\u017c K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH (2021) Metabolic-Associated fatty liver Disease (MAFLD), diabetes, and Cardiovascular Disease: associations with Fructose Metabolism and Gut Microbiota. Nutr 14(1):103. https:\/\/doi.org\/10.3390\/nu14010103","journal-title":"Nutr"},{"issue":"10","key":"10249_CR66","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/jgh.16337","volume":"38","author":"H Hayashi","year":"2023","unstructured":"Hayashi H, Sawada K, Tanaka H et al (2023) The effect of heat-killed Lactobacillus brevis SBL88 on improving selective hepatic insulin resistance in non-alcoholic fatty liver disease mice without altering the gut microbiota. J Gastroenterol Hepatol 38(10):1847\u20131854. https:\/\/doi.org\/10.1111\/jgh.16337","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10249_CR67","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.31032","volume":"71","author":"A Unalp-Arida","year":"2020","unstructured":"Unalp-Arida A, Ruhl CE (2020) Patatin-like Phospholipase Domain-Containing protein 3 I148M and Liver Fat and Fibrosis scores Predict Liver Disease Mortality in the U.S. Population. Hepatology 71(3):820\u2013834. https:\/\/doi.org\/10.1002\/hep.31032","journal-title":"Hepatology"},{"issue":"7","key":"10249_CR68","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/genes13071265","volume":"13","author":"W Zhao","year":"2022","unstructured":"Zhao W, Mori H, Tomiga Y et al (2022) HSPA8 Snucleotideepolymorphismrisism Is Associatedserum Serum concentrationratiocarotidaarteryAatherosclerosiserosnonalcoholicofatty liver diseaseisease. Genes (Basel) 13(7):1265. https:\/\/doi.org\/10.3390\/genes13071265","journal-title":"Genes (Basel)"},{"issue":"3","key":"10249_CR69","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/jcm10030467","volume":"10","author":"D Niederseer","year":"2021","unstructured":"Niederseer D, Wernly B, Aigner E, Stickel F, Datz C (2021) NAFLD and Cardiovascular diseases: Epidemiological, mechanistic and therapeutic considerations. J Clin Med 10(3):467. https:\/\/doi.org\/10.3390\/jcm10030467","journal-title":"J Clin Med"},{"issue":"11","key":"10249_CR70","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/jgh.16330","volume":"38","author":"Y Tian","year":"2023","unstructured":"Tian Y, Wang B (2023) Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies. J Gastroenterol Hepatol 38(11):1877\u20131885. https:\/\/doi.org\/10.1111\/jgh.16330","journal-title":"J Gastroenterol Hepatol"},{"key":"10249_CR71","doi-asserted-by":"publisher","unstructured":"Caddeo A, Spagnuolo R, Maurotti S MBOAT7 in liver and extrahepatic diseases. Liver Int 43:2351\u20132364. https:\/\/doi.org\/10.1111\/liv.15706","DOI":"10.1111\/liv.15706"},{"issue":"3","key":"10249_CR72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","volume":"13","author":"M Longo","year":"2022","unstructured":"Longo M, Meroni M, Paolini E et al (2022) TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants Impact on NAFLD Development and Progression both in patients and in in vitro models. Cell Mol Gastroenterol Hepatol 13(3):759\u2013788. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.11.007","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"19","key":"10249_CR73","doi-asserted-by":"publisher","first-page":"14653","DOI":"10.3390\/ijms241914653","volume":"24","author":"Y Shi","year":"2023","unstructured":"Shi Y, Qi W (2023) Histone modifications in NAFLD: mechanisms and potential therapy. Int J Mol Sci 24(19):14653. https:\/\/doi.org\/10.3390\/ijms241914653","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10249_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000447276","volume":"34","author":"E Scorletti","year":"2016","unstructured":"Scorletti E, Byrne CD (2016) Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2-Diabetes and Dysbiosis. Dig Dis 34(Suppl 1):11\u201318. https:\/\/doi.org\/10.1159\/000447276","journal-title":"Dig Dis"},{"issue":"1","key":"10249_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13(1):36\u201349. https:\/\/doi.org\/10.1038\/nrendo.2016.135","journal-title":"Nat Rev Endocrinol"},{"key":"10249_CR76","doi-asserted-by":"publisher","first-page":"154809","DOI":"10.1016\/j.prp.2023.154809","volume":"251","author":"M Ramezani","year":"2023","unstructured":"Ramezani M, Zobeiry M, Abdolahi S, Hatami B, Zali MR, Baghaei K (2023) A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression. Pathol Res Pract 251:154809. https:\/\/doi.org\/10.1016\/j.prp.2023.154809","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10249_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/mmr.2022.12922","volume":"27","author":"P Anggreini","year":"2023","unstructured":"Anggreini P, Kuncoro H, Sumiwi SA, Levita J (2023) Role of the AMPK\/SIRT1 pathway in nonalcoholic fatty liver disease (review). Mol Med Rep 27(2):35. https:\/\/doi.org\/10.3892\/mmr.2022.12922","journal-title":"Mol Med Rep"},{"issue":"6","key":"10249_CR78","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po E, Valenti L (2020) Update on NAFLD genetics: from new variants to the clinic. J Hepatol 72(6):1196\u20131209. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.020","journal-title":"J Hepatol"},{"issue":"5","key":"10249_CR79","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jceh.2018.10.004","volume":"9","author":"O Bedi","year":"2019","unstructured":"Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P (2019) Molecular and pathological events involved in the Pathogenesis of Diabetes-Associated nonalcoholic fatty liver disease. J Clin Exp Hepatol 9(5):607\u2013618. https:\/\/doi.org\/10.1016\/j.jceh.2018.10.004","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10249_CR80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/geriatrics5010008","volume":"5","author":"TA Alalwan","year":"2020","unstructured":"Alalwan TA (2020) Phenotypes of sarcopenic obesity: exploring the effects on Peri-muscular Fat, the obesity Paradox, hormone-related responses and the clinical implications. Geriatr (Basel) 5(1):8. https:\/\/doi.org\/10.3390\/geriatrics5010008","journal-title":"Geriatr (Basel)"},{"issue":"44","key":"10249_CR81","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3748\/wjg.v22.i44.9674","volume":"22","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Ballestri S, Guaraldi G et al (2016) Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 22(44):9674\u20139693. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9674","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10249_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0884533612470464","volume":"28","author":"RS Rahimi","year":"2013","unstructured":"Rahimi RS, Landaverde C (2013) Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract 28(1):40\u201351. https:\/\/doi.org\/10.1177\/0884533612470464","journal-title":"Nutr Clin Pract"},{"issue":"11","key":"10249_CR83","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/apt.15679","volume":"51","author":"R Loomba","year":"2020","unstructured":"Loomba R, Wong R, Fraysse J et al (2020) Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 51(11):1149\u20131159. https:\/\/doi.org\/10.1111\/apt.15679","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10249_CR84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68(2):268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003","journal-title":"J Hepatol"},{"issue":"3","key":"10249_CR85","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MEG.0b013e32834e8041","volume":"24","author":"Y Colak","year":"2012","unstructured":"Colak Y, Senates E, Ozturk O et al (2012) Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 24(3):255\u2013261. https:\/\/doi.org\/10.1097\/MEG.0b013e32834e8041","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10249_CR86","doi-asserted-by":"publisher","first-page":"e223146","DOI":"10.1148\/radiol.223146","volume":"309","author":"A Ozturk","year":"2023","unstructured":"Ozturk A, Kumar V, Pierce TT et al (2023) The future is Beyond Bright: the evolving role of quantitative US for fatty liver disease. Radiology 309(2):e223146. https:\/\/doi.org\/10.1148\/radiol.223146","journal-title":"Radiology"},{"key":"10249_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/gastro\/goae029","volume":"12","author":"S Ciardullo","year":"2024","unstructured":"Ciardullo S, Muraca E, Vergani M, Invernizzi P, Perseghin G (2024) Advancements in pharmacological treatment of NAFLD\/MASLD: a focus on metabolic and liver-targeted interventions. Gastroenterol rep 12:29. https:\/\/doi.org\/10.1093\/gastro\/goae029","journal-title":"Gastroenterol rep"},{"issue":"11","key":"10249_CR88","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1007\/s00210-024-03204-6","volume":"397","author":"M Bhardwaj","year":"2024","unstructured":"Bhardwaj M, Mazumder PM (2024) The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus. Naunyn Schmiedebergs Arch Pharmacol 397(11):8421\u20138443. https:\/\/doi.org\/10.1007\/s00210-024-03204-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10249-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:24:14Z","timestamp":1766852654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10249"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10249-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}